PRESS RELEASE, February 7, 2023 Carina Biotech to Present Preclinical Data at Lorne Cancer 2023 Supporting Effectiveness of LGR5-Targeted CAR-T Cell Therapy Platform in Ovarian Cancer Tumor Models Preclinical evidence
PRESS RELEASE Tuesday, January 24, 2023 Carina Biotech Receives FDA “Safe to Proceed” Letter for IND Application for Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate for Treatment
Carina Biotech files its first IND application for a CAR-T cell therapy targeting a solid cancer. The IND application is directed at a first-in-human Phase 1/2a clinical trial in advanced
Carina Biotech is extremely pleased to announce that it has raised $7.5 million at first close of its current funding round, welcoming on board new venture capital business Tenmile as
Figure 1. CAR-T cells versus the solid tumor microenvironment (from Foeng et al 2022). ____________ It is now no secret that chimeric antigen receptor (CAR)-T cell therapy has produced remarkable
Carina Biotech is pleased to announce that it has appointed Australian organisation Cell Therapies to undertake Good Manufacturing Processes (GMP) manufacture of its LGR5 CAR-T cells for a first-in-human clinical
Carina Biotech Symposium Program Wednesday, 18 May 2022 Hotel Grand Chancellor Adelaide + online Join from a PC, Mac, iOS or Android: https://unisa.zoom.us/j/86263467920?pwd=WXNCZCtTYkw4RTIyTUdNREpjbjlqZz09 Password: 720700 9:30 am – 10
PLEASE JOIN US on Wednesday, 18 May 2022 9:30 am – 5:00 pm for Carina Biotech's inaugural symposium Join us in Adelaide at the Hotel Grand Chancellor and virtually for Carina
Carina has had five abstracts accepted for poster presentations at the AACR Annual Meeting which will take place from April 8 to April 13. The poster presentations come after Carina’s
Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a
